All treatments
Treatment
Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory BCell Non Hodgkin Lymphoma (ZUMA-4)
This study is testing a new treatment called Tecartus for children and teenagers with certain types of blood cancer (leukaemia and lymphoma) that have come back after treatment. We want to see how safe it is and how well it works to help patients get better.
For: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Relapsed/Refractory B-cell non-Hodgkin lymphoma (r/r NHL)Spain · Czechia · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)
This study is looking at a new treatment called KTE-X19 for a type of cancer called Mantle Cell Lymphoma. It's for people whose cancer has come back or hasn't responded to previous treatments. Researchers want to see how well the new treatment shrinks the cancer.
For: Relapsed/Refractory Mantle Cell LymphomaFrance · Spain · Germany